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Abstract 
PARTIAL EXCHANGE TRANSFUSION FOR POLYCYTHEMIA HYPERVISCOSITY 
SYNDROME: A 21-YEAR REVIEW Bridget L. Hopewell, Laurie A. Steiner, Richard A. 
Ehrenkranz, Matthew J. Bizzarro, and Patrick G. Gallagher. Division of Perinatal 
Medicine, Department of Pediatrics, Yale University School of Medicine, New Haven, 
Connecticut. 
The objective of this study was to examine the use of partial exchange 
transfusion (PET) performed for polycythemia hyperviscosity syndrome (PHS) over 
time. A retrospective review of 141 infants who received a PET for PHS at Yale-New 
Haven Hospital, between 1986-2007 was performed, querying maternal and 
neonatal medical records. Patient demographics, risk factors for PHS, indications for 
PET, and complications associated with PET and PHS were collected. Overall, there 
was no change in the number of PET performed over the study period (r2=0.082, 
p=0.192). Eighty-eight percent of patients had at least one risk factor for PHS, most 
commonly maternal diabetes. Over time, there was a statistically significant 
decrease in maternal diabetes as a risk factor for PHS. Forty percent of patients had 
a significant complication attributed to PHS prior to PET. Eighteen percent of 
patients had a complication attributed to PET. Life-threatening complications of PHS 
or PET were rare. In conclusion, PHS continues to be a problem observed in 
neonatal intensive care units, particularly in at-risk populations. PHS and PET are 
associated with significant complications. Well designed studies with long-term 
follow up are needed to assess the risks and benefits of PET for PHS. 
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Introduction 
 Neonatal polycythemia, a condition in which the percentage of whole blood 
occupied by red blood cells is increased, is a diagnosis recognized since antiquity.  
The first case is thought to be a red first-born twin recorded in the Bible (Genesis 
25:25).  Though the condition has been known and recognized, interest has waxed 
and waned over the past few decades.  There was a flurry of research during the 
1970s and 1980s in which animal models were developed, some randomized trials 
were undertaken, diagnostic tools were developed and debated, and meetings 
abounded with controversy over both the diagnosis and treatment.  However, even 
though polycythemia is still a common problem, occurring in 1-5.4% of live births,1-6 
the literature has remained largely 
silent for the past 25 years, leaving 
many of the controversial 
questions unexplored.   
Because our clinical 
observations indicate that 
polycythemia continues to be a 
common diagnosis and both the 
condition and its treatment carry 
significant risks of morbidity, we 
felt it was time to re-explore this 
condition.   Our first step in re-
opening this topic for close examination was to determine how the research from 
Figure 1: Incidence of venous polycythemia 
(hct >/= 65%) by birth weight and 
gestational age groupings.1  
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the 1970s and 1980s affected the clinical practice here at Yale-New Haven Hospital. 
In addition, we wanted to further define the population affected and delineate their 
risks for morbidity. 
Definitions 
Polycythemia and Hyperviscosity are often used interchangeably though they 
are not equivalent.  Neonatal Polycythemia is significant only because it can lead to 
Hyperviscosity syndrome which can lead to alterations in blood flow, sludging of 
blood in vessels, clotting or ischemia, leading to end organ damage.  An increased 
concentration of red blood cells can lead to increased blood viscosity, but this is also 
affected by plasma proteins, red cell deformability, hypoxia, and acidosis.  The 
resulting associated constellation of clinical and laboratory findings is called 
polycythemia hyperviscosity syndrome (PHS).7   
Fetal Erythropoiesis 
Fetal erythropoiesis first begins in the yolk sac until the third to the sixth 
month when the liver takes over as the main source of erythropoiesis.  Bone 
marrow, the major site of adult erythropoiesis, becomes important during the last 3 
months of gestation.   
The most well-known difference between fetal erythrocytes and adult red 
blood cells (RBCs) is that the hemoglobin in fetal erythrocytes has a higher oxygen 
affinity which aids in transfer of oxygen from maternal to fetal RBCs.  In addition, 
they also differ in their membrane proteins, surface antigens, and metabolic enzyme 
patterns.  They also have a larger mean cell volume and mean cell hematocrit as 
compared to adult RBCs. 8  
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The fetus adapts to the relatively hypoxic intrauterine environment by 
increased erythropoiesis.9  As such, the red blood cell mass of a newborn infant 
compared to later infancy, childhood, and adulthood, is significantly increased.  
However, this physiologic increase in red blood cell mass can be pathologically 
increased by either primary (increased fetal erythropoietic activity) or secondary 
(transfusion of RBCs) causes, or reduced plasma volume, leading to polycythemia.10 
Blood Viscosity 
Viscosity of a newtonian fluid was described by Poiseuille as the ratio of 
shear stress to shear rate as such:11 
   Viscosity=   shear stress  =  (p-p1)r4pi 
             shear rate          8lQ 
where p-p1 is the pressure gradient along the blood 
vessel, r is the radius, l is the length of the blood vessel 
and Q is the blood flow.  Figure 2 shows the 
relationship of viscosity to hematocrit at high and low 
shear rates. 12 
However, blood is not a fully Newtonian fluid as 
it is a suspension of particles.  The viscosity of blood 
does not remain constant.  It varies with the amount of 
constituents, properties of those constituents, as well as features of the 
microenvironment of the circulation. Reliable viscometers are in development but 
are not currently in use clinical use. 13 
Figure 2: Hematocrit vs. 
viscosity 
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Plasma proteins can contribute to the viscosity of whole blood.  Adult 
hyperviscosity syndromes can sometimes be attributed to hyperproteinemia states 
like diabetes and Waldenstrom’s macroglobulinemia.14,15    However, these are not 
conditions observed in the newborn.  Increasing fibrinogen in plasma also 
correlates to an increase in viscosity.16  As such, the viscosity of plasma in the 
newborn is relatively constant at 1.0 to 1.5 centipose which is very near the 
viscosity of water, a Newtonian fluid.16,17  Linderkamp’s group saw in their analysis 
an overall decrease in plasma viscosity leading to decreased whole-blood viscosity 
in pre-term infants.  This led them to consider whether polycythemia was less 
dangerous in pre-term infants or whether pre-term infants required even lower 
viscosity to maintain adequate circulation. 16 
The deformability of the RBCs influence viscosity.  RBCs in a neonate have 
been shown to be more deformable than in an adult, but are also more variable in 
shape which leads to a heterogeneous population of RBCs with respect to their 
membrane deformability. 18  Aging RBC’s are less deformable than young RBC’s and 
this difference in deformability is exaggerated in neonates as compared to adults. 19 
The deformability of leukocytes (WBCs) also can influence whole blood 
viscosity.  Stimulated neutrophils are less deformable than resting neutrophils. 20,21  
Inflexible platelets might be suspected to contribute to viscosity.  Mean platelet 
volume has been shown to correlate with plasma viscosity in cardiac patients. 22 
Acidic pH (<7.00) increases blood viscosity.23  This may be due to fluid shifts 
into RBCs with decreasing pH.  It is hypothesized that along with increasing blood 
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volume, asphyxia-induced placental transfusion also decreases pH which 
compounds the increase in viscosity. 24 
The apparent viscosity of whole blood also varies with the size of the vessels.  
Blood flow is high in large vessels and the apparent viscosity is low, while in small 
blood vessels the apparent viscosity is high.  Changes in the hematocrit cause the 
greatest changes in viscosity in small blood vessels.  However, it has been known 
since the 1930s that viscosity decreases with decreasing size of the capillary25 down 
to 3µm.26  This represents high hemodynamic efficiency.  The hct of blood does not 
affect the viscosity in the capillary which means that in vitro measurements of blood 
viscosity may not reflect the viscosity of the blood in the capillary.24  It has been 
suggested that viscosity may increase again as the capillary size decreases below 4 
mm.  The variation in capillary size in different organs may explain the difference in 
effects of PHS on 
different organs.17 In 
addition, capillary and 
venous hemoglobin 
determinations are 
often quite discordant 
which hinders clinical 
decision making.  
Figure 3 shows 
simultaneous capillary and venous hemoglobin determinations for 24 newborn 
infants.27 
Figure 3: Comparison of capillary and venous 
hemoglobin in 24 infants 
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As blood viscosity is not easily or reliably measured clinically, the hematocrit 
is used as an imperfect measure of PHS and is used with clinical impression to 
decide on whether or not the child requires treatment.  Data has been difficult to 
interpret because of variation in studies including source of the blood sample and 
age of the infant at the time of measurement. 
Oh and Lind also showed in the 1960’s that capillary hematocrit was 
consistently 10% higher than simultaneously obtained peripheral venous samples.28  
Ramamurthy showed that 80% of infants with an umbilical vein hct >/= 63% have 
viscosity greater than three standard deviations above the mean and 94% of 
neonates with an umbilical vein hct <63% had viscosity in the normal range.  
However, capillary hct, which is usually the first measured in an infant had no 
significant correlation between peripheral vein hct or umbilical vein hct. 2  The ideal 
measurement would be the in vivo viscosity of blood in arterioles, venules, and 
capillaries of key organs,2 but as this is not accessible, we strive for something that 
will best correlate.  Commonly, a hematocrit of 65% or greater has been used to 
define polycythemia. 
The timing of the blood sample of the hct is important and can influence 
diagnosis because from birth to 6-12 hours of age, shifts in body water increase the 
hct, and then decrease the hct similar to the value at birth by about 24 hours. 2,29 
Hemodynamics 
Signs and symptoms of PHS are believed to be from disturbances in blood 
flow in different organs, and thus the hemodynamics have been examined in order 
to explain the difference in the effects of PHS on different organ systems.  There has 
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been no comprehensive study done on the hemodynamics of PHS and much is still 
unclear. 
With regards to the cardiovascular system, it has been observed in dog 
models that there is a decrease in cardiac output with relatively little change in 
oxygen transport or delivery. It has also been shown to increase pulmonary 
resistance and slightly increase systemic resistance, as well as decrease myocardial 
blood flow.30,31  These results have been substantiated in infants as well and the 
decreased cardiac output appears to be mostly a result of reduction of heart rate 
with possible reduction in stroke volume. 32,33  Fouron and Herbert used a lamb 
model to show that pulmonary resistance increases more than systemic resistance.  
They then showed that with a hct above 70%, the pulmonary and systemic 
resistance were the same.  This also reversed the direction of blood flow through the 
patent ductus arteriosus. 34 
Boehm et. al found that with increasing hematocrit, bile acid concentration in 
serum increased and trypsin and lipase activity in duodenal juice was decreased.  
These findings were greatest in the asymptomatic infants not treated with PET vs. 
symptomatic infants that were treated. 35  The authors warn that managing these 
infants nutritionally could be more difficult. 
Renal hemodynamics have been examined.  In hypervolemic polycythemia 
caused by delayed cord clamping, it was shown that there was higher renal blood 
flow, greater GFR and greater urine output.36  However, in a puppy model of 
normovolemic polycythemia, it was found that while renal blood flow was 
preserved, renal plasma flow decreased by 63% and Glomerular Filtration Rate 
8 
 
(GFR) decreased by 53% resulting in significantly decreased urine output as well as 
electrolyte excretion.  36  It has been hypothesized that the difference between these 
studies is that both volume status and hct affect renal hemodynamics. 24  Another 
study showed infants with PHS had decreased GFR, urine output, and sodium 
excretion which was ameliorated by PET. 37 
Whether peripheral circulation in the feet of infants with PHS is affected is 
not clear.  Some studies show no effect on peripheral circulation,38 while others 
show that at a given blood volume, an increase in viscosity decreases peripheral 
circulation.39 One study showed a decrease in peripheral blood flow which 
normalized with PET.  However, the infants were neither hypoxic nor hypercarbic 
before or after the exchange.40   
Doppler studies of cerebral circulation have shown that polycythemic infants 
have a significant reduction in cerebral blood flow velocity compared with similar 
term infants with normal hematocrits and blood viscosity values.  The velocity of the 
blood flow also improved after PET in this study. 41  In a newborn lamb model with 
induced polycythemia, the same group demonstrated that in polycythemic lambs, 
the arterial oxygen content was increased.  When the arterial oxygen content was 
reduced but the lamb remained polycythemic, the cerebral blood flow increased to 
baseline values.  This led them to suggest that the reduced flow observed may be 
caused by an increased oxygen content, rather than increased viscosity.42  
Limitations of most animal models are that polycythemia is induced after birth, 
rather than as a result of a hostile uterine environment. 
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Symptoms 
Symptoms of polycythemia-hyperviscosity are often nonspecific.  Many of the 
symptoms of PHS can also be attributed to other perinatal problems such as 
asphyxia or chronic hypoxia and may not be directly caused by PHS.  The presence 
of symptoms makes the diagnosis more likely, but the absence of symptoms does 
not preclude the diagnosis.  These symptoms include a ruddy complexion, lethargy, 
hypoglycemia, feeding difficulties, hyperbilirubinemia, thrombocytopenia, 
respiratory distress, cyanosis and seizures. Often the infants have a reddish-blue 
“ruddy” color in spite of a normal PaO2.  Major ischemic clotting events resulting in 
gangrenous necrosis have also been reported, and were detected antenatally and 
thus are resistant to treatment.43  The respiratory distress is hypothesized to be due 
to the elevated pulmonary vascular resistance and perhaps increased shunting in 
the lungs.   
In addition to poor feeding and vomiting which has been reported with PHS, 
necrotizing enterocolitis (NEC) has been associated with PHS in several studies.44,45  
However, in a population of patients admitted to a newborn special care unit 
already at increased risk for developing NEC, it is nearly impossible to attribute the 
development of NEC specifically to PHS.  Necrotizing enterocolitis could be 
hypothesized to be caused by either sludging of blood in vessels from PHS, 
disruption of flow from a partial exchange transfusion, or be unrelated due to 
significant other risk factors in this patient population.  One study in an animal 
model showed the incidence of NEC in polycythemic puppies was 58%.46  However, 
Black et al47  found that NEC occurred with higher frequency in patients who had 
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received an exchange transfusion, and furthermore found that one third of the 
infants had pneumatosis intestinalis.  Therefore, they argue NEC is caused by the 
exchange transfusion rather than hyperviscosity.  Large, prospective, randomized 
trials are needed to sort out these relative risks of NEC. 
Though renal hemodynamics do seem to be affected, acute renal failure is not 
seen frequently in infants with PHS, but it has been reported.48  As with necrotizing 
enterocolitis, acute renal failure may be multifactorial in origin and whether PHS is 
contributory or a confounding variable in cases of asphyxia or other risk factors has 
yet to be sorted out. 
Hypoglycemia is a common symptom in polycythemia.  Rosenkrantz, using 
his lamb model, has hypothesized it is due to a reduced plasma volume. 49  Since 
glucose is carried in the plasma, as plasma is reduced, so is glucose.  Furthermore, as 
blood flow is decreased, the extraction of glucose is increased compounding the 
problem.  Others have suggested that it is due to decreased glucose production 
resulting from hyperviscosity, though the mechanism is unclear. 50  Another 
hypothesis is that the excess of red blood cells causes excess glycolysis and 
increased consumption of glucose by the red blood cells themselves.   
Thrombocytopenia, fibrin monomers, and evidence of intravascular 
thromboplastic activity have been found in infants with PHS.51  One study found 
thrombocytopenia in 20% of infants with PHS, but they all had normal coagulation 
findings.6  Mechanisms have not been determined, but a clotting risk is hypothesized 
because of normally low antithrombin III levels combined with impairment of the 
microcirculation.52  However, low antithrombin levels are also seen in infants who 
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have been asphyxiated and it is unknown whether PHS is a confounding variable or 
an independent risk factor.   
In some studies, polycythemic infants have been reported to have worse 
developmental and neurologic outcomes than their non-polycythemic counterparts. 
In 1982, Black et al reported 38% incidence of motor and neurologic abnormalities 
in the infants with PHS compared to 11% of matched controls. 53  Asymptomatic 
infants with polycythemia have been shown to have increased pulmonary resistance 
and relative bradycardia which normalized after PET with no change in stroke 
volume thereby increasing cardiac output in those infants. 33  In his review, 
Rosenkrantz24 summarized the frequency of symptoms in 4 major studies as 
follows: 
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Table 1: Frequency of Clinical Symptoms Observed in Association with 
Polycythemia Investigation 
Clinical Symptoms Gross  
et al54 
(n=18) 
(%) 
Ramamurthy 
and Brans2 
(n=54) 
(%) 
Black  
et al53 
(n=111) 
(%) 
Goldberg  
et al55 
(n=20) 
(%) 
Cyanosis 89 17 7 Nr 
Plethora 83 63 Nr Nr 
Tremulous/jittery 67 13 Nr Nr 
Abnormal EEG 33 Nr Nr Nr 
Seizures 28 0 0 Nr 
Respiratory distress 44 4 10 15 
Cardiomegaly 17 Nr Nr 85 
Lethargy/poor 
feeding 
Nr 50 + 55 
Hyperbilirubinemia 50 6 Nr 5 
Abnormal blood 
smear 
50 Nr Nr Nr 
Thrombocytopenia 39 Nr Nr 25 
Hypoglycemia 33 Nr 27 40 
Hypocalcemia 6 Nr Nr 0 
Nr- not reported or examined 
+ - greater incidence compared with the control group 
 
Other reported clinical symptoms include irritability, hypotonia, easily 
startled, vomiting, hepatomegaly, and jaundice. 
Pathogenesis 
Many perinatal factors are associated with the development of polycythemia 
including conditions of intrauterine transfusion including twin-twin transfusion, 
maternal-fetal transfusion, and delayed cord clamping; conditions associated with 
increased fetal erythropoiesis such as acute and chronic fetal hypoxia, fetal trisomy, 
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and endocrine abnormalities.24,56,57 In a large series of infants of diabetic mothers, 
5% developed polycythemia.58  Causes of primary and secondary neonatal 
polycythemia are summarized in Table 2.59   
Table 2: Causes of primary and secondary neonatal polycythemia 
Causes of Primary Neonatal Polycythemia Causes of Secondary Neonatal 
Polycythemia 
 Intrauterine hypoxia 
        Placental insufficiency 
        Small for gestational age, growth 
retardation 
        Preeclampsia 
        Severe maternal heart disease 
        Maternal smoking 
Delayed cord clamping 
Maternal insulin-dependent diabetes Twin-to-Twin transfusion 
Neonatal thyrotoxicosis Maternal-fetal transfusion 
Congenital adrenal hyperplasia Dehydration 
High-altitude conditions Perinatal asphyxia 
Chromosome abnormalities 
        Trisomy 13 
        Trisomy 18 
        Trisomy 21 
        Hyperplastic viceromegaly (Beckwith-
Wiedemann syndrome) 
 
Decreased erythrocyte deformability  
 
Fetal hypoxia is thought to contribute to polycythemia in two ways.  First, it 
can shift blood from the placental circulation to the fetus, resulting in an increase of 
both red cell mass and blood volume.  Second, hypoxia may contribute to an 
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increase in fetal production of erythropoietin which stimulates development of 
more red cells by the fetus.  Examples of causes of chronic fetal hypoxia include 
maternal diabetes, intrauterine growth restriction (IUGR) or small for gestational 
age fetus (SGA), preeclampsia, placental insufficiency, neonatal thyrotoxicosis, 
maternal smoking, increased fetal metabolism, and living at high altitude. 
Smoking is thought to contribute to the development of PHS because of 
hypoxia resulting from a nicotine-induced reduction in uteroplacental blood flow as 
well as an increasing fetal carboxy-hemoglobin.  Hypoxia then is thought to increase 
erythropoietin production.  In addition, maternal smoking has been shown to 
decrease erythrocyte deformability. 60 Awonusonu et al. determined that term 
neonates of mothers who smoke during pregnancy require PET approximately two 
and a half times as often as term neonates of mothers who do not smoke. 60 
Conditions associated with erythrocyte transfusion such as twin-twin 
transfusion, maternal-fetal transfusion, and 
delayed cord clamping are also associated 
with PHS.61,62  The relationship between an 
infants blood volume and placental residual 
blood volume at various times of cord 
clamping has been known since 1969 as 
shown in Figure 4.61   One study showed 
14% of infants delivered outside the 
hospital developed polycythemia.63 
Figure 4: Infant and placental blood 
volume vs. time of cord clamping. 
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In addition, high altitude is associated with a higher incidence of 
polycythemia, presumably owing to the decreased partial pressure of oxygen.  It has 
been shown that the incidence of polycythemia in Denver, CO at 1610m above sea 
level was twice that at 
sea level in Virginia. 1,3  
Figure 5 shows a 
proposed schema for 
the etiology and 
pathogenesis of 
symptomatic 
hyperviscosity states in 
the neonate (RBC, red 
blood cells).54 
Complications 
Table 3: Complications associated with neonatal Polycythemia 
Complications Associated with Neonatal Polycythemia 
Respiratory distress syndrome 
Congestive heart failure 
Convulsions 
Peripheral gangrene 
Priapism 
Necrotizing enterocolitis 
Ileus 
Acute renal failure 
Abnormal electroencephalographic pattern 
Figure 5: Proposed schematic representation of the 
etiology and pathogenesis of hyperviscosity in the 
neonate 
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Treatment 
To improve clinical symptoms and potentially improve neurologic outcome, 
isovolemic hemodilution, often called partial exchange transfusion (PET) has been 
used to reduce the hematocrit.  A hematocrit of 60% is the goal of most PET.  The 
blood volume is calculated by this formula: 
   (Observed hematocrit – Desired hematocrit [60%]) 
             Observed Hematocrit 
The blood volume in the newborn infant is estimated at 80-100 mL/kg body weight.  
The usual process consists of attaching an empty syringe to the umbilical vein 
catheter and 5-20mL aliquots are withdrawn.  Then, another syringe with saline, 
Ringer’s Lactate, or plasma is infused at the same time or just after.  After each 
aliquot, a rest period of 5-10 minutes is taken in which the infant’s vital signs and 
clinical symptoms are monitored for any complications.  The last aliquot drawn is 
usually sent for a CBC.  No studies have shown an advantage for either fresh frozen 
plasma, albumin, or crystalloid solutions, however with the risk of infection from 
plasma, most physicians opt for crystalloid solutions, though it requires monitoring 
of electrolyte status. 
The rationale for PET is that reducing presumed hyperviscosity decreases 
vascular resistance, improves perfusion, and limits end organ damage, thereby 
preventing or ameliorating complications of PHS.32,41,64,65 PET may lead to 
improvement in symptomatology, such as cyanosis, hypoglycemia, 
thrombocytopenia, and cardiac function in the short term.6,33,66-68  PET has also been 
shown to increase skin capillary blood flow velocity in vivo especially when 
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performed shortly after birth, which is hypothesized to be reflective of other 
internal organ capillary blood flow.65  Interestingly, in the study of cerebral blood 
flow velocity which found the flow velocity was slower in infants with PHS than in 
nonpolycythemic infants, the polycythemic infants showed an increase in blood flow 
velocity and a reduction in vascular resistance after being treated with PET.41 
However, even with this evidence of immediate improvement, PET has not been 
shown to improve long term developmental outcomes in infants with PHS.66,67,69,70  
One study showed that for the first two weeks of life, infants treated with PET for 
PHS were less irritable, more alert and more easily consoled, but neonatal problems 
were not predictive of neurologic outcome at 8 months.55  In addition, one 
prospective randomized trial in 1985 showed an increase in abdominal distension 
and bloody emesis and bloody stools in hyperviscous patients receiving PET 
compared to hyperviscous patients receiving only symptomatic care.47  The lack of 
improvement in long term neurologic outcomes has caused many to question the 
utility of this procedure 71 in light of possible complications that have not been fully 
defined. 
Alternative treatments undertaken include watchful waiting, or increased 
fluid intake delivered enterally usually by gavage feeding, or parenterally. 
The American Academy of Pediatrics guidelines for PET in treatment of PHS 
are vague: “The accepted treatment of polycythemia is PET. However, there is no 
evidence that exchange transfusion affects long-term outcome.72 In the past 20 
years, there have been no studies in the English literature assessing the frequency 
with which PET for PHS is performed, the patient population undergoing PET, the 
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indications used for initiating PET, and the risks associated with PET.  Based on our 
longitudinal clinical observations, we hypothesized the following: PHS remains a 
common condition in neonatal intensive care units; PET continues to be used in the 
treatment of PHS; and both PHS and PET may be associated with neonatal 
morbidity. To address these hypotheses, we examined the frequency, indications, 
and complications of PET performed for PHS over the past 22 years at a single 
institution.   
We hope that our study will spur interest in designing controlled studies that 
will be more helpful in defining which infants will benefit from PET for PHS.  We 
also hope it will remind physicians that even procedures that have been done 
frequently have risks and help them weigh risks and benefits in their clinical 
decision making.  
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Hypotheses 
Based on review of the literature and the authors’ experience in the Yale-New Haven 
Children’s Hospital Newborn Special Care Unit, we hypothesize that PHS remains a 
common condition in neonatal intensive care units.  We also  hypothesize that PET 
continues to be used in the treatment of PHS.  We further hypothesize that both PHS 
and PET may be associated with neonatal morbidity. 
 
Specific Aims 
To address our hypotheses, we have developed these specific aims: 
1. Determine frequency of PET for PHS over 21 years at a single institution 
2. Evaluate demographic information of patients receiving PET 
3. Examine risk factors for developing PHS which necessitates PET 
4. Compare recorded indications for PET with recommended indications 
5. Examine complications attributable to PHS and/or PET
20 
 
Patients and Methods 
Infants who were long-term admissions (>24 hours) to the Newborn Special 
Care Unit (NBSCU) at Yale New Haven Children’s Hospital (YNHCH) from January 1, 
1986, through December 31, 2007, and received PET for PHS shortly after birth 
were included. Neonates who received a PET for anemia or a double volume 
exchange transfusion for any cause were excluded.  One infant with iatrogenic 
polycythemia was also excluded.  Charts from 141 infants who met criteria were 
reviewed.  During the entire study period, the NBSCU at Yale New Haven Children’s 
Hospital was under the same leadership of Dr. Ian Gross and Dr. Richard 
Ehrenkranz. 
Data collection included incidence of PET, patient and maternal 
demographics, known or suspected risk factors for developing PHS, physician 
recorded indication for PET, laboratory evaluation surrounding PET, complications 
possibly related to PHS, complications possibly related to PET, and comorbidities of 
patients receiving PET. In accordance with AAP Guidelines,72 asymptomatic patients 
were not screened for polycythemia. Blood viscosity was not measured. Data were 
collected in a de-identified manner using pre-designed data collection sheets and 
entered into a Microsoft Access Database for collection, review, and analysis. 
In order to conduct longitudinal comparison, groups were divided into two 
time periods. The early time period was January 1, 1986-December 31, 1996 and the 
later time period was January 1, 1997-December 31, 2007. These time periods were 
chosen as representative samples of obstetric practice, with the mid 1990’s 
representing a time demarking the widespread adoption of numerous advances in 
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prenatal care including ultrasound, Doppler techniques, fetal heart rate monitoring, 
cordocentesis, and management of the diabetic pregnancy.73,74 These changes were 
summarized in the review by Battaglia and Marconi in 1997 on “the new 
obstetrics.”73  
Risk Factors for Polycythemia Hyperviscosity Syndrome 
Mother and infants were assessed for the following risk factors for PHS: 
maternal diabetes, maternal hyperthyroidism, maternal smoking, maternal ethanol 
use, maternal substance abuse, maternal hypertension, pregnancy-induced 
hypertension, preeclampsia, intrauterine growth restriction, twin-twin transfusion 
syndrome, fetal trisomy or other genetic syndromes including Beckwith-
Weidemann syndrome, maternal fetal transfusion, delivery outside labor and 
delivery, perinatal asphyxia, delayed cord clamping, nuchal cord, cord stripping, 
neonatal hypothyroidism, and congenital adrenal hyperplasia.58,60,63,75-81 The 
diagnosis of intrauterine growth restriction was assigned using the criteria of 
Alexander et al.82 
Indications for Partial Exchange Transfusion 
Indications for PET during the study period were: 1) hematocrit of 70% or 
above with or without symptoms attributable to PHS; 2) hematocrit of 65% or 
above with symptoms attributable to PHS or; 3) at the discretion of the attending 
physician because of symptoms attributable to PHS independent of the 
hematocrit.2,83  Findings attributable to PHS included plethora, tachypnea, cyanosis, 
respiratory distress, feeding intolerance, and neurologic symptoms such as 
tremulousness, jitteriness, lethargy, hypoglycemia, or thrombocytopenia.  Data was 
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extracted from physician procedure notes to determine whether each patient was 
symptomatic.  There was a significant variation in whether capillary, peripheral 
venous or umbilical venous hct was used in determining whether the child should 
receive PET. 
During the entire 22 year study period, the protocol for partial exchange 
transfusion was the following: An umbilical venous catheter (UVC) was placed in a 
low lying position and a peripheral intravenous catheter (PIV) was inserted.  An 
infant’s total blood volume was assumed to be 85cc/kg body weight.  The volume of 
exchange, calculated as blood volume x (observed hematocrit – desired 
hematocrit)/observed hematocrit, was removed via the UVC while infusing the 
same volume of normal saline via either the PIV or an umbilical line. This technique, 
performed over an approximately 15 minute period, allows the patient to maintain 
euvolemia during the entire PET. Upon completion, the UVC was flushed with 
normal saline and removed unless there are other indications for its continued use. 
Ten percent dextrose was infused via the PIV for at least the next 6 hours while the 
patient receives no enteral feeds.  
Significant Complications of Polycythemia Hyperviscosity Syndrome or Partial 
Exchange Transfusion 
Complications that were possibly related to PHS or PET were analyzed.  PHS-
related complications were defined as any known complication of PHS present prior 
to PET. PET-related complications were defined as any complication, not present 
before PET, which occurred within 7 days after the PET.  However, in delayed-type 
complications like NEC, it was impossible to attribute it to either PET or PHS, and 
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was counted as a possible complication in both.   Complications of PHS or PET were 
defined as follows:  
Apnea: Cessation of respirations for > 20 seconds  
Bradycardia: Sustained heart rate < 100 bpm  
Tachycardia: Sustained heart rate > 180 bpm 
Seizures:  Clinical evidence of seizure-like activity treated with anti-seizure 
medication or EEG-documented seizures 
Symptomatic Hypotension: Decline in blood pressure requiring treatment with 
intravenous fluids or medication 
Pulmonary Hypertension: Respiratory distress with evidence of elevated right heart 
pressures by echocardiography or significant variation in pre- and post-ductal SpO2 
NEC:  Modified Bell’s criteria > stage 2a4,84-86 
Renal Failure: Urine output < 1 cc/kg/hr for > 24 hours or serum creatinine 
concentration >1.5 mg/dL 
Thrombotic or Ischemic Event: Significant disruption of blood flow due to vessel 
occlusion from thrombus diagnosed by Doppler ultrasound, contrast angiography, 
or magnetic resonance angiography 
Catheter Malfunction: Catheter thrombosis, rupture or dysfunction 
Severe thrombocytopenia: Platelet count < 50,000/mm3 
Hypoglycemia: Blood glucose < 50mg/dL  
Hypocalcemia: Serum calcium < 8.0mg/dL or plasma ionized calcium < 3.5mg/dL 
Hyperbilirubinemia: elevation of indirect bilirubin requiring treatment with 
phototherapy or double-volume exchange transfusion without other known causes 
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Intracranial Hemorrhage: Intracranial detected by ultrasound, computerized 
tomography or magnetic resonance imaging of the head 
PET-Related Mortality: PET-related mortality was defined as any death which was 
directly related to the PET and occurred within 7 days after the exchange.  
Statistical analysis 
The SPSS v13.0 statistical software package (SPSS Inc., Chicago, IL) and 
GraphPad Prism 3.0 (GraphPad Software, Inc., San Diego, CA) were utilized for data 
analyses.  Continuous data were compared using the Student t comparison of means. 
Dichotomous data were compared using a Pearson’s chi-square analysis or Fisher’s 
exact test when at least one cell contained a value <5. Trends were analyzed using 
linear regression analysis. A p-value of <0.05 was considered statistically significant.   
Infant Comorbidities 
Significant comorbidities including congenital heart disease, respiratory 
disease, genetic syndromes, sepsis not related to PHS or PET, IVH, renal disease or 
other significant morbidities were also collected. 
Laboratory Data 
Laboratory data were also collected including pre- and post-exchange 
hematocrit, hemoglobin, and platelet count. 
Human Subject Protection 
This study was approved by the Human Investigation Committee of the Yale 
University School of Medicine. 
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Statement of the responsibilities of the medical student for which this thesis is 
submitted 
Bridget Hopewell was responsible for requesting charts from medical 
records after a list of patients was generated from a database by another author.  
She then reviewed all charts and collected data.  All questions or concerns about 
individual charts were presented to other authors for verification and clarification.  
Ms. Hopewell entered all data into the Microsoft Access Database and together with 
Duncan Hopewell queried the data to make all reports, tables, and figures except for 
Figure 6 which required advanced statistical software and data on admissions that 
was queried and analyzed by another author. 
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Results 
From January 1, 1986 to December 31, 2007, there were 108,147 live births 
(mean 4915+351 births/year) at Yale New-Haven Children’s Hospital (YNHCH) and 
18,117 long term admissions, inborn and outborn, (mean 823+56 long term 
admissions/year) to the YNHCH Newborn Special Care Unit (NBSCU).  PET was 
performed in 169 infants. Twenty eight infants were excluded; 25 who underwent 
PET for anemia-related conditions or iatrogenic polycythemia, and 3 with 
incomplete medical records. The study group was composed of 141 patients who 
underwent PET for PHS shortly after birth.  
Patient characteristics are shown in Table 4. One hundred nine infants were 
singletons. Mean gestational age was 37.3 weeks (range 24-42 weeks). Mean birth 
weight was 2788g (range 680-4980g). Male:female ratio was 1:1.  Most patients had 
generally normal Apgar scores.  PET was mostly performed on Caucasian neonates, 
followed by Hispanic neonates and Black neonates.  Neonates were slightly smaller 
in weight in the later time period vs. the early time period.  There was a smaller 
percentage of Caucasian neonates in the later period.  There was also a decrease in 
the percentage of singletons and an increase in the percentage of multiple gestation 
patients receiving PET.  Finally, there was an increase in the percentage of patients 
born by caesarian section receiving PET.  Over the 22 year period, the number of 
PET/year/1000 live births was essentially unchanged. A slight downward trend was 
not statistically significant (r2 = 0.082, p=0.192, Figure 6).  PET was almost always 
performed in the first twenty-four hours of life.  The median time to the first 
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procedure was 9.0 hours.  The mean number of hours to the PET, 21.5, was skewed 
to the right because of some outliers. 
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Table 4: Perinatal Characteristics and Demographic Factors 
Perinatal 
Characteristics 
 All 
patients 
1986-1996 
N=82 
1997-2007 
N=59 
 Gestational 
Age (weeks)* 
37.3 ± 3.1 
 (n=138) 
37.8 ± 2.5 
 (n=80) 
36.6 ± 3.6 
 (n=58) 
 Birth weight 
(grams) 
2788 ± 871  
(n=139) 
2977±844 
(n=81) 
2524±847 
(n=58) 
 1 minute 
Apgar ≤5**   
16 (11%) 10 (12%) 6 (10%) 
 5 minute 
Apgar ≤7 ** 
11 (8%) 8 (10%) 3 (5%) 
Demographics**     
Sex  Male 70 (50%) 42 (51%) 28 (47%) 
 Female 71 (50%) 40 (49%) 31 (53%) 
Race White 83 (59%) 54 (66%) 29 (49%) 
 Black 11 (8%) 9 (11%) 2 (3%) 
 Hispanic 16 (11%) 10 (12%) 6 (10%) 
 Asian 2 (1%) 0 (0%) 2 (3%) 
 Other 3 (2%) 2 (3%) 1 (2%) 
 Not reported 24 (17%) 5 (6%) 19 (32%) 
Birth Order Singleton 109 (77%) 69 (84%) 40 (68%) 
 Twin A 7 (5%) 3 (4%) 4 (7%) 
 Twin B 18 (13%) 8 (10%) 10 (17%) 
 Triplet A 1 (1%) 0 (0%) 1 (2%) 
 Triplet C 4 (3%) 1 (1%) 3 (5%) 
 Not Reported 2 (1%) 1 (1%) 1 (2%) 
Mode of Delivery Vaginal 96 (68%) 62 (76%) 34 (58%) 
 C-Section 45 (32%) 20 (24%) 25 (42%) 
* Mean ± Standard Deviation 
** Number (Percent) 
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Several risk factors for neonatal polycythemia have been reported. Each 
patient’s chart was reviewed to determine which risk factors most commonly 
resulted in PHS requring PET at YNHH. The majority of patients (88%) had at least 
one risk factor for PHS (Table 5), with the most common risk factor being maternal 
diabetes. Other common risk factors included maternal hypertension, fetal trisomy, 
and unsupervised delivery (Table 5). Fifty four neonates (38%) had more than one 
risk factor. Comparing risk factors between the early and late time periods, there 
was a statistically significant decrease in maternal diabetes (p<0.01) in the later, 
more recent time period. 
Figure 6: Partial Exchange Transfusions Over Time.   
*r2=0.082, p=0.192 
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Table 5. Perinatal Risk Factors.  
Perinatal Risk Factor* Number 
(Percent) 
1986-1996  
(n=82) 
1997-2007 
(n=59) 
Maternal Diabetes 39 (28%) 29 (35%) 10 (17%)** 
Maternal Hypertension 25 (18%) 14(17%) 11 (19%) 
Maternal Substance abuse 16 (11%) 9 (11%) 7 (12%) 
Maternal Hypothyroidism 2 (1%) 0 (0%) 2 (3%) 
Placental Insufficiency 6 (4%) 0 (0%) 6 (10%) 
Twin-Twin Transfusion 10 (7%) 4 (5%) 6 (10%) 
Nuchal Cord 15 (11%) 11 (13%) 4 (7%) 
Unintended Delivery 
Outside Delivery Room/ 
Delayed Cord Clamping 
14 (10%) 8 (10%) 6 (10%) 
Intrauterine Growth 
Restriction 
48 (34%) 23 (28%) 25 (42%) 
Fetal Genetic Syndrome 19 (13%) 11 (13%) 8 (14%) 
Trisomy 21      15  8 7 
Trisomy 13        1  1 0 
Other                 3  2 1 
Other Risk Factors 4 (3%) 4 (5%) 0 (0%) 
Any Perinatal Risk Factor 121 (86%) 72 (88%) 49 (83%) 
* Number (Percent) 
**p<0.01 
 
There are no clear, evidence-based guidelines for when to initiate PET. 
Similar to other centers, in our institution, a PET is initiated for a hematocrit > 70% 
in the asymptomatic patient or for a hematocrit > 65% with symptoms attributed to 
PHS.20 During the study period, 50% of patients (n=71) received a PET because of a 
hematocrit > 70%. Thirty nine percent (n=55) received a PET because of a 
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hematocrit > 65% and symptoms attributed to PHS. The remaining patients (11%) 
underwent PET with a hematocrit between 60-65% and symtoms attributed to PHS. 
Mean hematocrits before and after PET were 69.7+4.2% and 57.3+5.8%, 
respectively. In contrast to previous studies which included mostly asymptomatic 
infants, due to our selection bias, the majority of the patients in our series had at 
least one clinical sign or symptom attributed to PHS in addition to an elevated 
hematocrit prior to PET (Table 6).24 The most common findings were 
hypoglycemia, plethora, tachypnea and jitteriness.  Because of the three accepted 
indications for PET, there was a wide range of hematocrits before and after 
transfusion as shown in Figure 7, but the mean hematocrit before transfusion was 
69, and the mean hematocrit after transfusion was 58. 
 
Figure 7: Hematocrits before and after PET.   
*The mean hematocrit before PET was 69 and the mean hematocrit after PET was 58 
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Table 6. Signs and Symptoms Attributed to Polycythemia Hyperviscosity 
Syndrome Before Perinatal Partial Exchange Transfusion.  
Signs and Symptoms Number 
(Percent) 
1986-1996  
(n=82) 
1997-2007 
(n=59) 
Hypoglycemia 41 (29%) 24 (29%) 17 (29%) 
Plethora 35 (25%) 22 (27%) 13 (22%) 
Tachypnea 19 (13%) 5 (6%) 14 (24%) 
Jitteriness 18 (13%) 11 (13%) 7 (12%) 
Cyanosis 13 (9%) 8 (10%) 5 (8%) 
Thrombocytopenia 8 (6%) 3 (4%) 5 (8%) 
Hypotonia 6 (4%) 0 (0%) 6 (10%) 
Apnea 4 (3%) 2 (2%) 2 (3%) 
Feeding intolerance 4 (3%) 2 (2%) 2 (3%) 
Lethargy 4 (3%) 3 (4%) 1 (2%) 
Other recorded 
indication 
16 (11%) 3 (4%) 13 (22%) 
Any sign or symptom 96 (68%) 51 (62%) 45 (76%) 
 
In addition to the signs and symptoms attributed to PHS described in Table 
6, several additional clinically significant complications of PHS have been described. 
These include cardiopulmonary and neurologic problems. In our series, over one 
third of patients (40%) had significant complications attributed to PHS prior to the 
inititation of PET (Table 7) including pulmonary hypertension, necrotizing 
enterocolitis, thrombotic/ischemic events, and severe thrombocytopenia. 
Hyperbilirubinemia was the most frequent complication (n=41, 29%). As the 
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median time from birth to PET was 9 hours, this finding re-enforces the suggestion 
that polycythemia can cause clinically significant jaundice, even on day of life one.     
Table 7: Complications Attributed to Polycythemia Hyperviscosity Syndrome 
Complication Number 
(Percent) 
1986-1996  
n=82 
1997-2007 
n=59 
Hyperbilirubinemia 41(29%) 26 (32%) 15 (25%) 
Pulmonary Hypertension 8 (6%) 4 (5%) 4 (7%) 
Necrotizing Enterocolitis 5 (4%) 2 (2%) 3 (5%) 
Thrombotic/Ischemic Event 2 (1%) 0 (0%) 2 (3%) 
Thrombocytopenia 2 (1%) 0 (0%) 2 (3%) 
Any Complication 56 (40%) 32(39%) 24 (41%) 
 
Few studies have examined the complications associated with PET, and those 
studies have focused on the GI complications, most notably necrotizing enterocolitis 
(NEC). In our study, PET-related complications were common, occurring in 25 
patients (18%) (Table 5). The most common were catheter-related complications. 
Other life-threating complications of PET were rare, but did occur (including sepsis 
and hypotension, Table 8). Similar to previous studies,67 we found an increased 
incidence of NEC after PET. Because PHS alone is a risk factor for NEC, it is 
impossible to determine if NEC would have occurred if PET had not been carried 
out. There were no statistically significant differences in complications between the 
two time periods studied.  
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Table 8. Complications Attributed to Partial Exchange Transfusion 
Complication Number 
(Percent) 
1986-1996  
n=82 
1997-2007 
N=59 
Catheter Complication 10 (7%) 4 (5%) 6 (10%) 
NEC 5   (4%) 2 (2%) 3 (5%) 
Thrombocytopenia 8   (6%) 2 (2%) 6 (10%) 
Suspected or Proven Sepsis 5   (4%) 5 (6%) 0 (0%) 
Hypotension 1   (1%) 1 (1%) 0 (0%) 
Any Complication  25  (18%) 8 (10%) 17 (29%) 
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Discussion 
These data demonstrate that PET for PHS continues to be a common 
procedure at YNHCH, without evidence for decline over two decades, representing 
the longest single-center, longitudinal documentation of trends in PET. They also 
document that the patient population undergoing PET was generally term neonates 
with one or more risk factors for PHS. A large number of patients had clinical 
symptoms consistent with PHS prior to PET. Since the AAP recommends against 
screening asymptomatic patients for polycythemia,72 our symptomatic patient 
population is likely representative of the majority of infants who currently undergo 
PET for PHS, yet previous studies of PET for PHS have focused on asymptomatic 
infants.66,87  
There are no randomized, controlled studies of the efficacy of PET done in 
symptomatic infants, and it is difficult to generalize studies of efficacy done on 
largely asymptomatic infants to a symptomatic popoulation. Although further 
studies of PET in symptomatic patients are necessary to determine whether PET 
provides a clinically significant, long term benefit, monitoring of high-risk 
populations to identify infants with symptomatic PHS is critical. Multiple studies 
have demonstrated that symptomatic patients with PHS are at risk for adverse 
neurologic outcomes,53,55,69 highlighting the need for careful developmental follow-
up of these infants even if they do not undergo PET.  These data are consistent with 
the hypothesis that in some patients, an adverse intrauterine environment or a 
significant perinatal event leads to tissue hypoxia, polycythemia, hyperviscosity, and 
irreversible tissue damage that would not be ameliorated by PET.7,66,69  Future 
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studies to compare infants with PHS caused by an adverse intrauterine environment 
leading to hypoxia and tissue damage with infants developing PHS because of a one-
time insult at birth like delayed cord clamping may be illuminating.   
The literature contains very little information regarding the safety of PET. A 
meta-analysis has demonstrated an increased risk of NEC following PET,67 but 
studies specifically detailing adverse events related to PET have not been done. 
Although the majority of the complications associated with PET in this series were 
minor, serious complications were observed. The possiblity of  serious 
complications from PET supports the practice of not doing PET on asymptomatic 
infants, who are unlikely to benefit from the procedure.  
The lack of data regarding the risks and benefits of PET makes it difficult to 
determine when to initiate a PET and the threshold hematocrit at which to perform 
a PET.88 The standard of care in many nurseries, outlined by Linderkamp,20 is to 
perform a PET when the venous hematocrit is ≥ 65% in an infant with symptoms of 
PHS or when the venous hematocrit is ≥ 70% in an asymptomatic infant, although 
there are little data to support this approach. In other institutions, PET is not 
performed in asymptomatic neonates until the hematocrit is > 75%. Part of the 
controversy over the threshold hematocrit stems from the fact that hematocrit is an 
imprecise method of determining blood viscosity and may be a poor indicator of 
who needs a PET. Polycythemia and hyperviscosity are not synonymous terms and 
many factors in addition to hematocrit, such as plasma proteins, leukocytes, 
fibrinogen, platelets, blood pH, and erythrocyte deformability can affect blood 
viscosity.16,17,23,24,38,56 Direct measurement of blood viscosity, measured using a 
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whole blood viscometer, is often not available in the clinical setting and thus the 
hematocrit is used as a surrogate marker. However, hematocrit is an imperfect 
measure of viscosity, as not all infants with an elevated hematocrit have increased 
blood viscosity.89 Given the risk of complications from both PHS and PET, a more 
precise test of blood viscosity is needed to better determine which patients might 
benefit from PET.  
As risk factors for PHS are diverse and include an unfavorable uterine 
environment leading to tissue hypoxia, endocrine abnormalities, genetic 
abnormalities as well as transfusion of erythrocytes, it is possible PHS is a more 
heterogeneous population.  As such, it is currently unclear whether the different risk 
factors for developing PHS lead to different outcomes, and would respond 
differently to PET.  It has been hypothesized that poor developmental outcomes are 
more related to a hostile uterine environment which also causes polycythemia, and 
thus would not respond to PET.67  Perhaps patients with PHS which develops from a 
harsh uterine environment and infants with PHS associated with erythrocyte 
transfusion represent separate populations.  A meta-analysis showed that delayed 
cord clamping by 2 minutes after birth did cause an increase in polycythemia that 
appeared to be asymptomatic.76  Our sample sizes were not large enough to 
separate and compare these different populations, but it is an area for further study. 
Additional factors contributing to the controversy in decision making in PHS 
include a lack of standardized diagnostic criteria for PHS, inconsistent study 
methodology, and variability in the methodology utilized for PET.  Data are not 
available to determine whether reducing the hematocrit leads to improvements in 
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long term outcome, as well controlled studies comparing long term follow up in 
symptomatic and asymptomatic infants treated with PET to those treated 
expectantly, are not available. 
Our data exemplify the advantages and disadvantages of single-center 
observational studies. The longitudinal collection of data over more than two 
decades has allowed us to analyze trends in treatment of PHS with PET over time. 
Limitations of this study include its retrospective nature, relatively small sample 
size, lack of long term developmental follow up data, and a lack of a specific control 
group for these patients. We have tried to clearly define complications from PHS and 
PET. However, due to the large amount of overlap in symptomatology, it is 
impossible to truly define a complication as resulting entirely from PET, as PHS may 
have also contributed to its occurrence. It is also possible that complications 
attributed to PHS or PET were due to other unknown causes, especially since our 
population consisted of complex patients admitted to the NBSCU.  It should 
therefore be recognized that complications cannot be attributed with absolute 
certainty within the limits of this retrospective chart review.  Confounding is 
therefore possible in our study, and further controlled investigation into 
complications could help elucidate the attributable risk of complications specific to 
PHS and PET. 
We conclude that PHS remains a common problem, particularly in at-risk 
populations. Both PHS and PET are associated with clinically significant 
complications. Despite its frequency, treatment of PHS with PET remains 
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controversial. Additional controlled studies with long term follow up are needed to 
assess the benefits of PET for PHS.      
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